CD274 and melanoma: Immunological mechanisms may also be responsible for early reports of clinical benefits from combination therapy with the anti-PD-L1 antibody atezolizumab and the MEK inhibitor cobimetinib in patients with BRAFV600E mutant and BRAF wild-type melanoma.